Supernus Pharmaceuticals, Inc. Share Price & Technical Analysis
SUPN · $48.21 (-2.37%)
Healthcare / Drug Manufacturers - Specialty & Generic
$48.21
-2.37%
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Pa…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
0% return in May, -7% avg return in past 3 year May month.
0% return in 2026, 20% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -3% | 13% | -4% | -7% | 0% | – | – | – | – | – | – | – | 0% |
| 25 | 6% | -15% | 3% | 0% | 0% | -1% | 12% | 30% | 6% | 16% | -18% | 9% | 48% |
| 24 | -4% | 7% | 14% | -12% | -10% | -1% | 11% | 18% | -11% | 10% | 7% | -1% | 28% |
| 23 | 13% | -8% | -2% | 2% | -10% | -9% | 2% | 4% | -14% | -13% | 15% | 6% | -15% |
| 22 | 6% | 3% | 12% | -14% | 0% | 2% | 10% | 8% | -1% | 1% | 7% | -4% | 31% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.91B
P/E ratio
—
52W high
$59.68
52W low
$30.83
Volume
5,26,838
Beta
0.57
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Supernus Pharmaceuticals, Inc. share price today?
- Supernus Pharmaceuticals, Inc. (SUPN) last traded around $48.21 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SUPN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SUPN. Download the app for real-time alerts.
- How can I analyze Supernus Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.